Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva SA (NASDAQ:IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro.
Inventiva SA (納斯達克：IVA) 股票週一交易上漲，成交量較高，爲855萬，而平均成交量爲0.991萬，根據Benzinga Pro的數據。
The company announced it has secured financing of immediately 94.1 million euros ($99.36 million) and up to 348 million euros ($379.55 million) to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor.
該公司宣佈已獲得立即9410萬歐元（9936萬美元）和最高34800萬歐元（37955萬美元）的融資，用於完成第3期NATiV3 MASH試驗併爲潛在的蘿非布瑞諾(NATiV3)的營銷批准以及商業化做準備。
The Transaction was led by New Enterprise Associates, BVF Partners LP, and Samsara BioCapital, with the participation of additional existing and new investors.
交易由新企業協會(New Enterprise Associates)、BVF Partners LP和Samsara BioCapital領導，其他現有和新投資者也參與其中。
Also Read: Why Is Inventiva's Stock Trading Higher on Monday?
閱讀更多：爲什麼Inventiva的股票週一交易上漲？
Pursuant to the Transaction and subject to shareholder approval at the next general meeting to be convened by December 16, 2024, the company appointed Mark Pruzanski as Chairman and Srinivas Akkaraju as director.
根據交易並經股東在2024年12月16日召開的下次股東大會批准，公司任命Mark Pruzanski爲董事長，Srinivas Akkaraju爲董事。
Each of the other four largest investors is to name up to four additional directors, of whom at least two will qualify as independent and would replace existing directors (excluding Frederic Cren, Mark Pruzanski, and Srini Akkaraju).
其他四大股東將各自提名最多四名額外董事，其中至少兩名需符合獨立條件，並將取代現有董事（不包括Frederic Cren、Mark Pruzanski和Srini Akkaraju）。
The company also estimates that, before the Transaction, it would need approximately 250 million euros to finance its activities until the topline results from its NATiV3 trial, targeted for the second half of 2026.
公司還估計，在交易之前，需要大約25000萬歐元來資助其活動，直到預計於2026年下半年公佈其NATiV3試驗的最終結果。
This estimate includes an estimated 130 million-135 million euros needed to finance the company's activities over the next 12 months mentioned above.
此估計包括用於在上述未來12個月內資助公司活動的約13000萬-13500萬歐元。
In February, Inventiva announced it stopped enrolling new patients in the NATiV3 Phase 3 trial for lanifibranor in non-alcoholic steatohepatitis (NASH) due to a reported serious adverse reaction. This reaction involved elevated liver enzymes in a patient undergoing treatment.
Inventiva在二月宣佈，由於一名正在接受治療的患者報告出現嚴重不良反應，停止了蘭非布魯諾在非酒精性脂肪肝（NASH）的第三階段試驗NATiV3的新患者註冊。這種反應涉及患者肝酶升高。
In March, the company lifted the previously disclosed voluntary pause on screening and randomization of its NATiV3 clinical trial, and sites are resuming screening activities.
三月份，該公司解除了先前披露的對NATiV3臨床試驗篩選和隨機化的自願暫停，各研究中心正在恢復篩選活動。
Price Action: At last check on Monday, IVA stock was up 31.20% at $2.48.
股價表現：截至週一最後檢查時，IVA股票上漲了31.20%，報2.48美元。
- Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?
- 爲什麼慢性疾病爲重點的Jasper Therapeutics股票在星期一交易時走高？
